AstraZeneca PLC American Depositary Shares (AZN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Should You Buy, Sell or Hold AstraZeneca Stock Before Q1 Earnings?
AZN's key medicines, mainly cancer drugs, Lynparza, Tagrisso and Imfinzi, are expected to have driven the company's top line.
AstraZeneca's quarterly earnings may undershoot; tariffs and a trade war pose the bigger obstacle
AstraZeneca PLC (LSE:AZN) is due to report first-quarter earnings on April 29, and UBS is bracing for a modest miss against market expectations, though the bank maintains a broadly supportive stance on the UK-listed drugmaker. Analysts at the Swiss investment bank expect group revenue and core operating profit to come in around 1% and 2% below Visible Alpha consensus, respectively, with softer-than-expected sales from diabetes drug Farxiga and rare disease treatment Soliris weighing on performance.
Trump inflicts a £9bn blow to the UK drug sector with tariff threat
Donald Trump has inflicted a £9 billion blow on the UK drug sector. That's the collective impact on the valuations of AstraZeneca PLC (LSE:AZN) and GSK PLC (LSE:GSK, NYSE:GSK), which dropped sharply in early trading on Wednesday,y after Donald Trump said the US would soon impose “a major tariff on pharmaceuticals”.
AZN Gets EU Nod for Expanded Use of Two Separate Cancer Drugs
The European Commission approves AstraZeneca's Enhertu for a new breast cancer indication while also expanding Imfinzi label in lung cancer.
AstraZeneca's Innovation Ecosystem: From Blockbusters To The Next Generation Of Therapy
AstraZeneca achieved record revenue growth of 18% in 2024, driven by key products like Farxiga and Tagrisso, and numerous regulatory approvals. The company's diversified portfolio spans oncology, CVRM, respiratory, vaccines, and rare diseases, with a strong global market presence and innovative, high-margin products. Financially robust, AstraZeneca's revenue reached $54.1 billion, with a 34% increase in operating profit, and a stable debt position, supporting future growth and dividends.
AstraZeneca and GSK shares rise on possible escape from new US tariffs
UK pharmaceutical giants AstraZeneca PLC (LSE:AZN) and GSK PLC (LSE:GSK, NYSE:GSK) shares both avoided the wider sell-off on Thursday morning on hopes that drug imports will escape the new 'reciprocal tariffs'. Based on a clarifying fact sheet produced by the White House alongside President Trump's announcement, it appears that pharmaceutical products imported into the US will be exempt from higher-rate tariffs "At least for now," says analyst Sean Conroy at Shore Capital.
AstraZeneca remains top pick with leading American bank. Here's why
AstraZeneca PLC (LSE:AZN) has kept its spot as Bank of America's top pick in the pharmaceutical sector, with analysts raising their earnings forecasts and praising the company's “best-in-class” drug pipeline. The bank reiterated its 'buy' rating and lifted its price target to 14,500p, pointing to a 28% upside from current levels.
Healthy Returns: AstraZeneca cholesterol pill shows promise as race with Merck heats up
AstraZeneca's new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.
AstraZeneca's Imfinzi Gets FDA Nod for Bladder Cancer Indication
The FDA approves AZN's sBLA seeking the expanded use of Imfinzi for adult patients with muscle-invasive bladder cancer.
Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol?
AstraZeneca said Monday its experimental pill lowered "bad" LDL cholesterol by 51%. The results could buoy AstraZeneca stock.
Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug
The Japanese Ministry of Health, Labour and Welfare on Thursday approved BridgeBio Pharma, Inc.‘s BBIO acoramidis, under the brand name Beyonttra, for adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).
Brokers Suggest Investing in Astrazeneca (AZN): Read This Before Placing a Bet
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
